Title of Research
First Trimester Screening for Preeclampsia and Prevention with Aspirin Prophylaxis
Start Date
16-11-2018 9:30 AM
End Date
16-11-2018 11:30 AM
Abstract
Abstract
Background: Preeclampsia is a hypertensive disorder of pregnancy affecting multiple organ systems complicating 2-8% of pregnancies. It is defined as new-onset hypertension and proteinuria, or hypertension and significant end-organ dysfunction, typically presenting after 20 weeks of gestation. It is caused by placental and maternal vascular dysfunction and resolves with delivery of the fetus. Maternal and fetal/placental factors have been studied for their ability to aid in the early detection of preeclampsia.
Objectives: The purpose of this literature review was to determine if early screening and detection of preeclampsia would allow for appropriate clinical management and pharmacological prophylaxis interventions to be implemented, ultimately to reduce maternal and fetal complications and preterm delivery.
Method: An integrative literature review was conducted undergoing an extensive search to identify maternal risk factors, biophysical measurements and biochemical markers for the development of an early screening test for the detection of preeclampsia. A total of 2 databases were used to acquire relevant sources: PubMed and CINHAL and a total of 12 articles were reviewed.
Results: Combined maternal and fetal/placental factors have shown higher detection rates for preeclampsia than when tested individually. This review suggests combining maternal risk factors, uterine artery resistance Doppler analysis and PAPP-A and placental growth factor (PlGF) biomarkers to have the highest detection rates in their ability to be used as a first trimester screening test for preeclampsia.
Conclusions: Specific combined factors could be useful in the early detection of preeclampsia allowing for the initiation of aspirin in high-risk women. However, more research is needed to determine whether these measurements could be clinically useful and improve patient outcomes.
Keywords: preeclampsia, risk factors, biomarkers, aspirin
Included in
First Trimester Screening for Preeclampsia and Prevention with Aspirin Prophylaxis
Abstract
Background: Preeclampsia is a hypertensive disorder of pregnancy affecting multiple organ systems complicating 2-8% of pregnancies. It is defined as new-onset hypertension and proteinuria, or hypertension and significant end-organ dysfunction, typically presenting after 20 weeks of gestation. It is caused by placental and maternal vascular dysfunction and resolves with delivery of the fetus. Maternal and fetal/placental factors have been studied for their ability to aid in the early detection of preeclampsia.
Objectives: The purpose of this literature review was to determine if early screening and detection of preeclampsia would allow for appropriate clinical management and pharmacological prophylaxis interventions to be implemented, ultimately to reduce maternal and fetal complications and preterm delivery.
Method: An integrative literature review was conducted undergoing an extensive search to identify maternal risk factors, biophysical measurements and biochemical markers for the development of an early screening test for the detection of preeclampsia. A total of 2 databases were used to acquire relevant sources: PubMed and CINHAL and a total of 12 articles were reviewed.
Results: Combined maternal and fetal/placental factors have shown higher detection rates for preeclampsia than when tested individually. This review suggests combining maternal risk factors, uterine artery resistance Doppler analysis and PAPP-A and placental growth factor (PlGF) biomarkers to have the highest detection rates in their ability to be used as a first trimester screening test for preeclampsia.
Conclusions: Specific combined factors could be useful in the early detection of preeclampsia allowing for the initiation of aspirin in high-risk women. However, more research is needed to determine whether these measurements could be clinically useful and improve patient outcomes.
Keywords: preeclampsia, risk factors, biomarkers, aspirin